Characterizing complication risk from multisite, intermittent transfusions for the treatment of sickle cell disease

Amy Tang

Jane Branscomb

Mei Zhou

Angela Snyder

James Eckman

First published: 18 July 2019

https://doi.org/10.1002/pbc.27921

Funding information:

This publication was supported by cooperative agreement number NU58 DD001138, funded by the Centers for Disease Control and Prevention. The Sickle Cell Data Collection Program in Georgia is made possible by support from the CDC Foundation (Sanofi Inc., Global Blood Therapeutics, Pfizer and Doris Duke Charitable Foundation; grant number CDC‐RFA‐OT18‐1802).